What is the appropriate dosing regimen for an artemisinin‑based combination therapy (ACT) kit (artemether‑lumefantrine) for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Artemether-Lumefantrine (ACT Combi Kit) Dosing Regimen

For adults and children >35 kg with uncomplicated P. falciparum malaria, administer artemether-lumefantrine as 4 tablets (80 mg artemether/480 mg lumefantrine) given at 0,8,24,36,48, and 60 hours (total of 24 tablets over 60 hours), taken with fatty food or drink. 1

Weight-Based Dosing Algorithm

Adults and Children ≥35 kg

  • 4 tablets per dose (each tablet = 20 mg artemether + 120 mg lumefantrine)
  • Day 1: 4 tablets at hour 0, then 4 tablets at hour 8
  • Day 2: 4 tablets at hour 24 (morning), then 4 tablets at hour 36 (evening)
  • Day 3: 4 tablets at hour 48 (morning), then 4 tablets at hour 60 (evening)
  • Total: 24 tablets over 72 hours 1, 2

Pediatric Dosing (Weight-Based)

The dosing is strictly weight-based for children, not age-based, as middle age/weight bands have higher rates of dosing errors 3:

  • 5 to <15 kg: 1 tablet per dose (6 doses over 60 hours)
  • 15 to <25 kg: 2 tablets per dose (12 tablets total)
  • 25 to <35 kg: 3 tablets per dose (18 tablets total)
  • ≥35 kg: 4 tablets per dose (24 tablets total) 1, 2

Critical Administration Requirements

Food is mandatory: Artemether-lumefantrine must be taken with a fatty meal or drink to ensure adequate absorption. This is non-negotiable as lumefantrine absorption is highly fat-dependent 1, 2. Without fat, bioavailability drops significantly, risking treatment failure.

Supervised dosing: Day 7 lumefantrine concentrations are 44% lower with unsupervised treatment 4. The first dose should ideally be directly observed, and adherence counseling is essential.

High-Risk Populations Requiring Close Monitoring

Three groups have increased treatment failure risk and warrant enhanced surveillance 4:

  1. Very young children (<3 years), especially those underweight-for-age who have 23% lower drug concentrations than adequately nourished children and 53% lower than adults
  2. Patients with high parasitemia (>135,000/μL or >4-5%)
  3. Patients in areas with emerging artemisinin resistance or very low transmission intensity

For these populations, consider checking Day 7 lumefantrine levels if available; therapeutic threshold is ≥200 ng/mL for >98% cure rates 4.

Important Caveats and Drug Interactions

QT prolongation risk: Avoid in patients with:

  • Known QT prolongation or risk factors
  • Concomitant medications that prolong QT (macrolides, antiarrhythmics, certain antidepressants)
  • Electrolyte abnormalities 1, 2

Contraindicated combinations 2:

  • Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) reduce artemether, DHA, and lumefantrine exposure by 68-89%
  • CYP2D6 substrates that prolong QT (flecainide, tricyclic antidepressants)

Pregnancy: Can be used in all trimesters per WHO and CDC guidelines 1

Pharmacokinetic Rationale

The six-dose regimen achieves 87-97% corrected cure rates versus 74-87% with the older four-dose regimen 5. Artemether has rapid parasite clearance (half-life ~2 hours) while lumefantrine provides sustained coverage (half-life 3-6 days) 2. The combination prevents resistance development through complementary mechanisms of action 1.

Dosing on mg/kg basis in children (≥5 to <35 kg) produces comparable systemic exposure to adults when following the weight-based bands 2, 6.

Monitoring and Follow-Up

  • Assess clinical response at 3 days; if no improvement, consider alternative diagnosis or treatment failure
  • Day 7 follow-up recommended, especially for high-risk groups
  • Monitor for post-artesunate delayed hemolysis (PADH) in severe malaria cases transitioned to oral therapy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.